FLT3 Inhibitors in Development for AML
Harry Erba, MD, PhD, professor of medicine, director, Hematologic Malignancy Program, University of Alabama at Birmingham, discusses the excitement around FLT3 inhibitors for the treatment of acute myeloid leukemia (AML).
Clinical Pearls
Harry Erba, MD, PhD, professor of medicine, director, Hematologic Malignancy Program, University of Alabama at Birmingham, discusses the excitement around FLT3 inhibitors for the treatment of acute myeloid leukemia (AML).
- 25-30% of patients with AML with normal karyotype will have activating mutations in FLT3.
- Sorafenib has shown activity in FLT3/ITD-positive AML.
- Quizartinib has shown high response rates as monotherapy, though data have shown responses tend to be mostly complete remissions with incomplete blood count recovery.
- Quizartinib may be an important agent to bridge patients to an allogeneic stem cell transplant, which would be the only curative option for patients with relapsed FLT3/ITD-positive AML.
- Patients who respond to quizartinib can develop a D835 mutation, but an agent is being developed that is active against both FLT/ITD and D835 mutations.
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More
